21 . March , 2019 - Thursday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Ethosuximide Oral Solution

Big Image Dosage Form: Oral solution

Ethosuximide Description

Ethosuximide is an anticonvulsant succinimide, chemically designated as alpha-ethyl-alpha-methyl-succinimide, with the following structural formula:

C7H11NO2 M.W. 141.17.

Ethosuximide is a white to off-white crystalline powder, having a characteristic odor. It is freely soluble in water and chloroform and very soluble in alcohol and in ether.

Each teaspoonful (5 mL), for oral administration, contains 250 mg Ethosuximide, USP. Also contains: citric acid, anhydrous; FD&C red No. 40; FD&C yellow No. 6; artificial raspberry flavor; glycerin; purified water; saccharin sodium; sodium benzoate; sodium citrate; sucrose.

Ethosuximide - Clinical Pharmacology

Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.

Indications and Usage for Ethosuximide

Ethosuximide oral solution is indicated for the control of absence (petit mal) epilepsy.

Contraindications

Ethosuximide should not be used in patients with a history of hypersensitivity to succinimides.

Warnings

Blood dyscrasias, including some with fatal outcome, have been reported to be associated with the use of Ethosuximide; therefore, periodic blood counts should be performed. Should signs and/or symptoms of infection (e.g., sore throat, fever) develop, blood counts should be considered at that point. Ethosuximide is capable of producing morphological and functional change in the animal liver. In humans, abnormal liver and renal function studies have been reported. Ethosuximide should be administered with extreme caution to patients with known liver or renal disease. Periodic urinalysis and liver function studies are advised for all patients receiving the drug.

Cases of systemic lupus erythematosus have been reported with the use of Ethosuximide. The physician should be alert to this possibility.

Usage in Pregnancy

Reports suggest an association between the use of anticonvulsant drugs by women with epilepsy and an elevated incidence of birth defects in children born to these women. Data are more extensive with respect to phenytoin and phenobarbital, but these are also the most commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs.

The reports suggesting an elevated incidence of birth defects in children of drug-treated epileptic women cannot be regarded as adequate to prove a definite cause and effect relationship. There are intrinsic methodologic problems in obtaining adequate data on drug teratogenicity in humans; the possibility also exists that other factors, e.g., genetic factors or the epileptic condition itself, may be more important than drug therapy in leading to birth defects. The great majority of mothers on anticonvulsant medication deliver normal infants. It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorder are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although it cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo or fetus.

The prescribing physician will wish to weigh these considerations in treating or counseling epileptic women of childbearing potential.

Precautions

General

Ethosuximide, when used alone in mixed types of epilepsy, may increase the frequency of grand mal seizures in some patients.

As with other anticonvulsants, it is important to proceed slowly when increasing or decreasing dosage, as well as when adding or eliminating other medication. Abrupt withdrawal of anticonvulsant medication may precipitate absence (petit mal) status.

Information for Patients

Ethosuximide may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a motor vehicle or other such activity requiring alertness; therefore, the patient should be cautioned accordingly.

Patients taking Ethosuximide should be advised of the importance of adhering strictly to the prescribed dosage regimen.

Patients should be instructed to promptly contact their physician if they develop signs and/or symptoms (e.g., sore throat, fever) suggesting an infection.

Drug Interactions

Since Ethosuximide may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (e.g., Ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease Ethosuximide levels).

Pregnancy

See WARNINGS.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 3 years have not been established. (See DOSAGE AND ADMINISTRATION.)

Adverse Reactions

Gastrointestinal System

Gastrointestinal symptoms occur frequently and include anorexia, vague gastric upset, nausea and vomiting, cramps, epigastric and abdominal pain, weight loss, and diarrhea. There have been reports of gum hypertrophy and swelling of the tongue.

Hemopoietic System

Hemopoietic complications associated with the administration of Ethosuximide have included leuokpenia, agranulocytosis, pancyopenia, with or without bone marrow suppression, and eosionphilia.

Nervous System

Neurologic and sensory reactions reported during therapy with Ethosuximide have included drowsiness, headache, dizziness, euphoria, hiccups, irritability, hyperactivity, lethargy, fatigue, and ataxia.

Psychiatric or psychological aberrations associated with Ethosuximide administration have included disturbances of sleep, night terrors, inability to concentrate, and aggressiveness. These effects may be noted particularly in patients who have previously exhibited psychological abnormalities. There have been reports of paranoid psychosis, increased libido, and increased state of depression with overt suicidal intentions.

Integumentary System

Dermatologic manifestations which have occurred with the administration of Ethosuximide have included urticaria, Stevens- Johnson syndrome, systemic lupus erythematosus, pruritic erythematous rashes, and hirsutism.

Special Senses

Myopia.

Genitourinary System

Vaginal bleeding, microscopic hematuria.

Overdosage

Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. A relationship between Ethosuximide toxicity and its plasma levels has not been established. The therapeutic range of serum levels is 40 mcg/mL to 100 mcg/mL, although levels as high as 150 mcg/mL have been reported without signs of toxicity.

Treatment

Treatment should include emesis (unless the patient is or could rapidly become obtunded, comatose, or convulsing) or gastric lavage, activated charcoal, cathartics and general supportive measures. Hemodialysis may be useful to treat Ethosuximide overdose. Forced diuresis and exchange transfusions are ineffective.

Ethosuximide Dosage and Administration

Ethosuximide oral solution is administered by the oral route. The initial dose for pediatric patients 3 to 6 years of age is one teaspoonful (250 mg) per day; for pediatric patients 6 years of age and older, 2 teaspoonfuls (500 mg) per day. The dose thereafter must be individualized according to the patient’s response. Dosage should be increased by small increments. One useful method is to increase the daily dose by 250 mg every four to seven days until control is achieved with minimal side effects. Dosages exceeding 1.5 g daily, in divided doses, should be administered only under the strictest supervision of the physician. The optimal dose for most pediatric patients is 20 mg/kg/day. This dose has given average plasma levels within the accepted therapeutic range of 40 to 100 mcg/mL. Subsequent dose schedules can be based on effectiveness and plasma level determinations.

Ethosuximide oral solution may be administered in combination with other anticonvulsants when other forms of epilepsy coexist with absence (petit mal). The optimal dose for most pediatric patients is 20 mg/kg/day.

How is Ethosuximide Supplied

Ethosuximide Oral Solution, USP, 250 mg/5 mL, is available in a raspberry flavored, red-orange colored syrup, in pint containers.

Dispense in a tight, light- resistant container, as defined in the USP.

Store at controlled room temperature between 20° and 25°C (68° and 77°F) (see USP). Protect from freezing and light.

Manufactured By:

TEVA PHARMACEUTICALS USA

Sellersville, PA 18960

Rev. E 10/2003


Ethosuximide (Ethosuximide)
PRODUCT INFO
Product Code 0093-9660 Dosage Form SOLUTION
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Ethosuximide (Ethosuximide) Active 250 MILLIGRAM  In 5 MILLILITER
citric acid Inactive  
anhydrous Inactive  
FD&C Red No. 40 Inactive  
FD&C Yellow No. 6 Inactive  
artificial raspberry flavor Inactive  
glycerin Inactive  
water Inactive  
saccharin sodium Inactive  
sodium benzoate Inactive  
sodium citrate Inactive  
sucrose Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0093-9660-16 473 MILLILITER In 1 CONTAINER None

Revised: 11/2006

Recent Drug Updates at DrugIndexOnline:





Canasa Canasa
Generic name: Mesalamine Brand names: Pentasa, Asacol, Canasa, Rowasa Why is Canasa prescribed? Rowasa Suspension Enema, Pentasa, and Asacol are used to treat mild to moderate ulcerative colitis (inflammation of the large intestine and rectum). Rowasa Suspension Enema is also prescribed for infl more...

dapsone topical dapsone topical
Generic Name: dapsone topical (dap zone top ick all) Brand Names: Aczone What is dapsone topical? Dapsone topical is an antiinfective medication. Dapsone topical is a medicine used to help treat acne. Dapsone topical may also be used for purposes other than those listed in this medicatio more...

Gen-Bromazepam Gen-Bromazepam
Some commonly used brand names are: In the U.S.— Alprazolam Intensol 1 Ativan 12 Dalmane 9 Diastat 7 Diazepam Intensol 7 Dizac 7 Doral 16 Halcion 18 Klonopin 5 Librium 3 Lorazepam Intensol 12 Niravam 1 Paxipam 10 ProSom 8 Restoril 17 Serax 14 Tranxene-SD 6 Tranxene-SD Half Strength 6 Tran more...

Hytuss Hytuss
Some commonly used brand names are: In the U.S.— Anti-Tuss Breonesin Diabetic Tussin EX Fenesin Gee-Gee Genatuss Glycotuss Glytuss Guiatuss Halotussin Humibid L.A. Humibid Sprinkle Hytuss Hytuss-2X Naldecon Senior EX Organidin NR Pneumomist Robitussin Scot-tussin Expectorant Sinumist-SR T more...

Labetalol HCl Labetalol HCl
Pronouncation: (la-BET-uh-lahl HIGH-droe-KLOR-ide) Class: Alpha-adrenergic blocker, Beta-adrenergic blocker Trade Names: Trandate - Tablets 100 mg - Tablets 200 mg - Tablets 300 mg - Injection 5 mg/mL Apo-Labetalol (Canada) Mechanism of Action Pharmacology Selectively blocks alpha-1 receptor more...

Meloxicam Suspension Meloxicam Suspension
Generic Name: Meloxicam Suspension (mel-OX-i-kam) Brand Name: Mobic Meloxicam Suspension is a nonsteroidal anti-inflammatory drug (NSAID). It may cause an increased risk of serious and sometimes fatal heart and blood vessel problems (eg, heart attack, stroke). The risk may be greater if you alre more...

Poliovirus Vaccine Live Oral Poliovirus Vaccine Live Oral
Some commonly used brand names are: In the U.S.— Ipol 2 Orimune 3 Other commonly used names are: eIPV IPV N-IPV OPV Sabin vaccine Salk vaccine TOPV Note: For quick reference, the following poliovirus vaccines are numbered to match the corresponding brand names. This informati more...

Propoxyphene Propoxyphene
Pronouncation: (pro-POX-ee-feen) Class: Opioid analgesic Propoxyphene Hydrochloride Trade Names: Darvon-N - Tablets 100 mg (as napsylate) Trade Names: Darvon Pulvules - Capsules 65 mg (as hydrochloride) 642 (Canada) Mechanism of Action Pharmacology Relieves pain by stimulating opiate receptors in C more...